Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

364
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
364
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

236
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
236
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Mir452</i> protects against septic acute kidney injury by targeting <i>Apaf1</i> to relieve CASP9-mediated suppression of autophagy.

Autophagy·2026
Same author

Cobalt-catalyzed asymmetric three-component reductive addition of alkynes with alkyl halides and imines.

Nature communications·2026
Same author

Modulation of Exciton Transport in Few-Layer and Bulk Tungsten Disulfide under Hydrostatic Pressure.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Associations of daily sedentary time with mental health and sleep quality in adolescents: analyses of interaction and moderation effects.

BMC psychology·2026
Same author

Patterns of health-promoting lifestyles among patients with colorectal cancer: A latent profile analysis.

Asia-Pacific journal of oncology nursing·2026
Same author

Decoding the spatiotemporal dynamics of tumor immune niche remodeling in cancer immunotherapy.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 23, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Empagliflozin: a potential anticancer drug.

Wenwen Wu1, Yanyan Wang2, Jun Xie3

  • 1School of Life Sciences, Jiangsu Normal University, Xuzhou, Jiangsu, 221116, China.

Discover Oncology
|July 12, 2023
PubMed
Summary

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, shows anticancer effects by inhibiting tumor cell proliferation and migration. This diabetes drug also holds promise for cancer therapy.

Keywords:
AnticancerCancer therapyEmpagliflozinSGLT2 inhibitor

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

612

Related Experiment Videos

Last Updated: Jul 23, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

612

Area of Science:

  • Oncology
  • Pharmacology
  • Endocrinology

Background:

  • Empagliflozin is a well-tolerated sodium-glucose cotransporter 2 (SGLT2) inhibitor used for diabetes treatment.
  • Beyond glycemic control, empagliflozin exhibits cardioprotective, hypotensive, anti-inflammatory, and antioxidative stress effects.
  • Emerging research indicates potential anticancer properties of empagliflozin.

Purpose of the Study:

  • To review the anticancer effects of empagliflozin.
  • To explore the potential of empagliflozin as a therapeutic agent in cancer treatment.

Main Methods:

  • Review of existing scientific literature on empagliflozin and its effects on cancer cells.
  • Analysis of studies investigating SGLT2 expression in various cancer cell lines.
  • Evaluation of empagliflozin's impact on tumor cell proliferation, migration, and apoptosis.

Main Results:

  • Sodium-glucose cotransporter 2 (SGLT2) is expressed in multiple cancer cell lines.
  • Empagliflozin demonstrates significant inhibitory effects on specific tumor cell types.
  • Observed effects include inhibition of proliferation, reduced migration, and induction of apoptosis in cancer cells.

Conclusions:

  • Empagliflozin exhibits promising anticancer effects, including antiproliferative and pro-apoptotic activities.
  • The findings suggest empagliflozin could be a valuable therapeutic option for cancer treatment, in addition to its established roles in diabetes and heart failure management.
  • Further research is warranted to fully elucidate empagliflozin's anticancer mechanisms and clinical utility.